240
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Relationship Between Time in Range and Dusk Phenomenon in Outpatients with Type 2 Diabetes Mellitus

, , , , &
Pages 1637-1646 | Received 02 Mar 2023, Accepted 25 May 2023, Published online: 06 Jun 2023

References

  • Yapanis M, James S, Craig ME, O’Neal D, Ekinci EI. Complications of diabetes and metrics of glycemic management derived from continuous glucose monitoring. J Clin Endocrinol Metab. 2022;107(6):e2221–e2236. doi:10.1210/clinem/dgac034
  • Klimontov VV, Semenova JF. Glucose variability in subjects with normal glucose tolerance: relations with body composition, insulin secretion and sensitivity. Diabetes Metab Syndr. 2022;16(1):102387. doi:10.1016/j.dsx.2022.102387
  • Zhang J, Yang J, Liu L, et al. Significant abnormal glycemic variability increased the risk for arrhythmias in elderly type 2 diabetic patients. BMC Endocr Disord. 2021;21(1):83. doi:10.1186/s12902-021-00753-2
  • Rodbard D. Glucose variability: a review of clinical applications and research developments. Diabetes Technol Ther. 2018;20(S2):S25–S215. doi:10.1089/dia.2018.0092
  • Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A. The Dawn phenomenon, an early morning glucose rise: implications for diabetic intraday blood glucose variation. Diabetes Care. 1981;4(6):579–585. doi:10.2337/diacare.4.6.579
  • Rybicka M, Krysiak R, Okopień B. The Dawn phenomenon and the Somogyi effect - two phenomena of morning hyperglycaemia. Endokrynol Pol. 2011;62(3):276–284.
  • Bolli GB, Gerich JE. The “Dawn phenomenon”--a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med. 1984;310(12):746–750. doi:10.1056/nejm198403223101203
  • Li W, Du SN, Shi MJ, Sun ZZ. Spontaneous and transient predinner hyperglycemia in some patients with diabetes: dusk phenomenon. Medicine. 2016;95(47):e5440. doi:10.1097/md.0000000000005440
  • Du S, Shi MJ, Sun ZZ, Li W. Clinical diagnosis for dusk phenomenon of diabetes. Medicine. 2018;97(34):e11873. doi:10.1097/md.0000000000011873
  • Mian Z, Hermayer KL, Jenkins A. Continuous glucose monitoring: review of an innovation in diabetes management. Am J Med Sci. 2019;358(5):332–339. doi:10.1016/j.amjms.2019.07.003
  • Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388(10057):2254–2263. doi:10.1016/s0140-6736(16)31535-5
  • Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359(14):1464–1476. doi:10.1056/NEJMoa0805017
  • Bao S, Bailey R, Calhoun P, Beck RW. Effectiveness of continuous glucose monitoring in older adults with type 2 diabetes treated with basal insulin. Diabetes Technol Ther. 2021;24(5):299–306. doi:10.1089/dia.2021.0494
  • Aleppo G, Beck RW, Bailey R, et al. The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin. Diabetes Care. 2021;44(12):2729–2737. doi:10.2337/dc21-1304
  • Monnier L, Colette C, Sardinoux M, Baptista G, Regnier-Zerbib A, Owens D. Frequency and severity of the Dawn phenomenon in type 2 diabetes: relationship to age. Diabetes Care. 2012;35(12):2597–2599. doi:10.2337/dc12-0385
  • Monnier L, Colette C, Dejager S, Owens D. Magnitude of the Dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care. 2013;36(12):4057–4062. doi:10.2337/dc12-2127
  • Huang Y, Xu Y, Qiu J, et al. The impact of dusk phenomenon on total glucose exposure in Chinese people with type 2 diabetes. Medicine. 2021;100(13):e25298. doi:10.1097/md.0000000000025298
  • Wang JS, Lee IT, Lee WJ, et al. The Dawn phenomenon in type 2 diabetes: its association with glucose excursions and changes after oral glucose-lowering drugs. Ther Adv Chronic Dis. 2021;12:20406223211033674. doi:10.1177/20406223211033674
  • O’Neal TB, Luther EE. Dawn Phenomenon. In: StatPearls. StatPearls PublishingCopyright © 2022, StatPearls Publishing LLC; 2022.
  • Scheiner G, Boyer BA. Characteristics of basal insulin requirements by age and gender in Type-1 diabetes patients using insulin pump therapy. Diabetes Res Clin Pract. 2005;69(1):14–21. doi:10.1016/j.diabres.2004.11.005
  • Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593–1603. doi:10.2337/dci19-0028
  • Advani A. Positioning time in range in diabetes management. Diabetologia. 2020;63(2):242–252. doi:10.1007/s00125-019-05027-0
  • Runge AS, Kennedy L, Brown AS, et al. Does time-in-range matter? Perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes. Clin Diabetes. 2018;36(2):112–119. doi:10.2337/cd17-0094
  • Agiostratidou G, Anhalt H, Ball D, et al. Standardizing clinically meaningful outcome measures beyond HbA(1c) for Type 1 diabetes: a consensus report of the american association of clinical endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care. 2017;40(12):1622–1630. doi:10.2337/dc17-1624
  • Valenzano M, Cibrario Bertolotti I, Valenzano A, Grassi G. Time in range-A1c hemoglobin relationship in continuous glucose monitoring of type 1 diabetes: a real-world study. BMJ Open Diabetes Res Care. 2021;9(1):e001045. doi:10.1136/bmjdrc-2019-001045
  • Shah VN, Snell-Bergeon JK, Demmitt JK, et al. Relationship between time-in-range, HbA1c, and the glucose management indicator in pregnancies complicated by type 1 diabetes. Diabetes Technol Ther. 2021;23(12):783–790. doi:10.1089/dia.2021.0093
  • Sakai T, Aoyama K, Inazumi K, et al. Time in range correlates glycated albumin measured immediately after 2 weeks of continuous glucose monitoring. J Diabetes Complications. 2021;35(8):107962. doi:10.1016/j.jdiacomp.2021.107962
  • Ohigashi M, Osugi K, Kusunoki Y, et al. Association of time in range with hemoglobin A1c, glycated albumin and 1,5-anhydro-d-glucitol. J Diabetes Investig. 2021;12(6):940–949. doi:10.1111/jdi.13437
  • Vigersky RA, McMahon C. The relationship of hemoglobin A1C to time-in-range in patients with diabetes. Diabetes Technol Ther. 2019;21(2):81–85. doi:10.1089/dia.2018.0310
  • Peng HM, Deng HR, Zhou YW, et al. 血糖变异性对1型糖尿病患者葡萄糖目标范围内时间与血糖管理指标关系的影响 [Impacts of glycemic variability on the relationship between time in range and estimated glycated hemoglobin in patients with type 1 diabetes mellitus]. Zhonghua Yi Xue Za Zhi. 2022;102(16):1190–1195. Chinese. doi:10.3760/cma.j.cn112137-20211009-02236
  • Tokutsu A, Okada Y, Torimoto K, Tanaka Y. Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study. Diabetol Metab Syndr. 2020;12:70. doi:10.1186/s13098-020-00577-5
  • Piona C, Marigliano M, Mozzillo E, et al. High glycemic variability is associated with worse continuous glucose monitoring metrics in children and adolescents with type 1 diabetes. Horm Res Paediatr. 2021;94(9–10):369–373. doi:10.1159/000521430
  • Lu J, Ma X, Zhou J, et al. Association of time in range, as assessed by continuous glucose monitoring, with diabetic retinopathy in type 2 diabetes. Diabetes Care. 2018;41(11):2370–2376. doi:10.2337/dc18-1131
  • Yang J, Yang X, Zhao D, Wang X, Wei W, Yuan H. Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy. J Diabetes Investig. 2021;12(5):828–836. doi:10.1111/jdi.13394
  • Li F, Zhang Y, Li H, et al. TIR generated by continuous glucose monitoring is associated with peripheral nerve function in type 2 diabetes. Diabetes Res Clin Pract. 2020;166:108289. doi:10.1016/j.diabres.2020.108289
  • Yin X, Zhu W, Liu C, et al. Association of continuous glucose monitoring-derived time in range with major amputation risk in diabetic foot osteomyelitis patients undergoing amputation. Ther Adv Endocrinol Metab. 2022;13:20420188221099337. doi:10.1177/20420188221099337
  • Xie P, Deng B, Zhang X, et al. Time in range in relation to amputation and all-cause mortality in hospitalised patients with diabetic foot ulcers. Diabetes Metab Res Rev. 2022;38(2):e3498. doi:10.1002/dmrr.3498
  • Lu J, Ma X, Shen Y, et al. Time in range is associated with carotid intima-media thickness in type 2 diabetes. Diabetes Technol Ther. 2020;22(2):72–78. doi:10.1089/dia.2019.0251
  • Shen Y, Wang C, Wang Y, et al. Association between time in range and cancer mortality among patients with type 2 diabetes: a prospective cohort study. Chin Med J. 2021;135(3):288–294. doi:10.1097/cm9.0000000000001740